摘要:
La présente invention concerne des dérivés de thiazolidinedione, leurs procédés de préparation, et leur usage thérapeutique pour la prévention ou le traitement des cancers, et plus spécifiquement les cancers du sein. Ces composés sont de formule (I) et présentent, à une concentration de 100 µM, une viabilité hépatocytaire de préférence supérieure à 60 %, de préférence supérieure à 80%, et plus préférentiellement supérieure à 85%.
摘要:
La présente invention concerne un procédé de préparation de nebivolol et plus particulièrement un procédé amélioré de synthèse d'une alpha-halocétone de Ia formule (I) intermédiaire clé dans la préparation de nebivolol.
摘要:
The present invention relates to a novel method for the treatment of neoplasia, including cancer and other diseases and conditions in humans and mammals. More particularly, in preferred aspects, the present invention provides a method for the use of prenylcysteine analogs for the treatment of neoplasia, hyperproliferative cell growth including psoriasis, restenosis following cardiovascular surgery, hyperplasia, including renal hyperplasia, chronic inflammatory diseases including rheumatoid and osteoarthritis, among others.
摘要:
The invention relates to a method for producing chromane derivatives that are devoid of enantiomers and are substituted in position 2, from corresponding chromane-2-carboxylic acid esters.
摘要:
The present invention relates to non-steroidal ligands for use in nuclear receptor-based inducible gene expression system, and a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising: a DNA binding domain; a ligand binding domain; a transactivation domain; and a ligand is contracted with a DNA construct comprising: the exogenous gene and a response element; wherein the exogenous gene is under the control of the response element and binding of the DNA binding domain to the response element in the presence of the ligand results in activation or suppression of the gene.
摘要:
A class of benzopyrancarboxylic acid derivatives comprises compounds that are potent agonists of PPAR alpha and/or gamma, and are therefore useful in the treatment, control or prevention of non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, obesity, vascular restenosis, inflammation, and other PPAR alpha and/or gamma mediated diseases, disorders and conditions.
摘要:
Amide derivatives represented by the following general formula (1) which have a C5 alpha receptor antagonism, wherein each symbol has the meaning as defined in the description. These amide derivatives, optically active isomers thereof or pharmaceutically acceptable salts of the same are useful as preventives and remedies for diseases or syndromes caused by inflammation induced by C5 alpha [for example, immunological diseases such as rheumatism and systemic lupus erythematosus, allergic diseases such as sepsis, adult respiratory distress syndrome, chronic obstructive pulmonary disease and asthma, atherosclerosis, heart infarction, brain infarction, psoriasis, Alzheimer's disease and important organistic breakdown (for example, pneumonia, nephritis, hepatitis, pancreatitis) induced by leukocyte activation caused by ischemic reperfusion, burn or surgical invasion]. Moreover, they are useful as preventives and remedies for infection with bacteria and viruses mediated by C5 alpha receptor.
摘要:
The present invention relates to a process for ihe preparation of 6-f!uoro-3,4-dihydro- 2H-chromene-2-carbaidehyde which is useful as an Intermediate in the synthesis of Nebivolol or its pharmaceutical acceptable salts.
摘要:
Compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others.
摘要:
The present invention relates to a novel method for the treatment of neoplasia, including cancer and other diseases and conditions in humans and mammals. More particularly, in preferred aspects, the present invention provides a method for the use of prenylcysteine analogs for the treatment of neoplasia, hyperproliferative cell growth including psoriasis, restenosis following cardiovascular surgery, hyperplasia, including renal hyperplasia, chronic inflammatory diseases including rheumatoid and osteoarthritis, among others.